申请人:JANSSEN PHARMACEUTICA NV
公开号:US20160052939A1
公开(公告)日:2016-02-25
The present invention is directed to compounds of Formula I: wherein X is N or CR1; Y is N or CR2; R1 is H, alkoxy, halo, triazolyl, pyrimidinyl, oxazolyl, isoxazole, oxadiazolyl, or pyrazolyl; R2 is H, alkyl, alkoxy, or halo; Z is NH or O; R3 is H, alkyl, alkoxy, halo, or triazolyl; R4 is H or alkyl; or R3 and R4, together with the atoms to which they are attached, form a 6-membered aryl ring or a 5- or 6-membered heteroaryl ring; R5 is pyridyl, pyrazinyl, or pyrimidinyl, wherein the pyridyl, pyrazinyl, or pyrimidinyl is optionally substituted with halo or alkyl; and n is 1 or 2. Methods of making the compounds of Formula I are also described. The invention also relates to pharmaceutical compositions comprising compounds of Formula I. Methods of using the compounds of the invention are also within the scope of the invention.
本发明涉及式I的化合物:其中X为N或CR1; Y为N或CR2; R1为H、烷氧基、卤素、三唑基、嘧啶基、噁唑基、异噁唑基、氧化二唑基或吡唑基; R2为H、烷基、烷氧基或卤素; Z为NH或O; R3为H、烷基、烷氧基、卤素或三唑基; R4为H或烷基; 或R3和R4连同它们所连接的原子形成一个6元芳基环或5-或6元杂芳基环; R5为吡啶基、吡嗪基或嘧啶基,其中吡啶基、吡嗪基或嘧啶基可以选择地用卤素或烷基取代; n为1或2。还描述了制备式I化合物的方法。本发明还涉及包括式I化合物的制药组合物。使用本发明的化合物的方法也属于本发明的范围。